Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
You may want to ask whether you need prior authorization
Offered in tablet form, Hernexeos becomes the first oral targeted therapy for NSCLC patients whose tumors have activating HER2 (ERBB2) mutations and who have received at least one prior line of systemic therapy
The time it takes to fall asleep often improves, though the extent varies significantly between people
No payment required to schedule pay only after your visit is approved
doi: 10.1371/journal.pone.0021827 277 ToK.CaoR.YegiazaryanA.OwensJ.NguyenT.SasaniniaK.et al
US$ 23.24
US$ 26.36
US$ 27.64
